Hayrunnisa Bekis Bozkurt
Research Subjects
Hayrunnisa Bekis Bozkurt has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Çiğdem Eda Balkan Bozlak
Department of Microbiology, Kafkas University Faculty of Medicine, Kars, Türkiye
6 shared publications - Mustafa Arga
Department of Pediatric Allergy and Immunology, İstanbul Medeniyet University Faculty of Medicine Göztepe Prof. Dr. Süleyman Yalçın City Hospital Istanbul Turkey
4 shared publications - Müferet Ergüven
Department of Pediatric Rheumatology, Duzce University Faculty of Medicine , Duzce
4 shared publications - Ozlem Cavkaytar
Department of Pediatric Allergy and Immunology, Faculty of Medicine Istanbul Medeniyet University Istanbul Turkey
4 shared publications - Zafer Bıçakçı
Department of Pediatric Hematology&Oncology, Atatürk University Faculty of Medicine, Erzurum, Türkiye
3 shared publications - Azize Pınar Metbulut
Pediatric Immunology and Allergy Department, Ankara Bilkent City Hospital, Ankara, Turkey
2 shared publications
Latest Publications
- Open Access
- 13 April 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1754093
Systematic review of hematopoietic stem cell transplantation in patients with ataxia telangiectasia: a case report and an individual patient-level analysis
Background: There is a lack of clinical data on hematopoietic stem cell transplantation (HSCT) in Ataxia-Telangiectasia (A-T) patients due to the underlying chromosomal instability that leads to low tolerance to chemotherapy. To effectively manage cancer and immune risks, there is a need for improved HSCT protocols, novel therapies, and long-term monitoring. This report describes a 16-year-old boy with A-T and T-ALL who achieved long-term leukemia-free survival after HSCT using a tailored, drug-monitored conditioning regimen. His results were analyzed in the context of a systematic review of the literature on HSCT outcomes in A-T patients. Methods: A thorough literature review was conducted using a comprehensive search of the PubMed, Scopus, and Google Scholar databases. The search was limited to studies published between September 1, 2000, and September 1, 2025. Eligible studies were required to involve human participants and to include at least one patient with a confirmed diagnosis of A-T, with transplantation interventions. Results: The analysis included 16 A-T patients, including our patient, who underwent HSCT. The median age at transplantation was 48 months (interquartile range [IQR]: 22–142 months). Myeloablative conditioning (MAC) was administered to two patients, both of whom died. Reduced-intensity conditioning (RIC) was utilized for nine patients, with three deaths (33.3%). Reduced-toxicity conditioning (RTC) was administered in two patients, with one patient experiencing a fatal outcome. In total, eight patients (50%) experienced significant drug-related toxicities, eight (50%) had GvHD and only eight patients (50%) survived. Our patient underwent HSCT of a matched sibling donor after administration of adjusted treosulfan doses (cumulative AUC of 4671 mg/Lxh), and achieved leukemia-free survival with complete hematological and normalized thymic function without graft-versus-host disease (GvHD). Conclusion: Despite the historically poor survival outcomes observed in transplanted A-T patients, new HSCT strategies, such as treosulfan therapeutic drug monitoring and personalized drug profiles to select potent but less toxic agents, warrant reevaluation to achieve durable remission in leukemia and lymphoma. These findings underscore the necessity to persist in the development of innovative HSCT approaches with the objective of expanding therapeutic options for both malignancies and combined immunodeficiency.
- 13 April 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1754093
Open AccessSystematic review of hematopoietic stem cell transplantation in patients with ataxia telangiectasia: a case report and an individual patient-level analysis
Background: There is a lack of clinical data on hematopoietic stem cell transplantation (HSCT) in Ataxia-Telangiectasia (A-T) patients due to the underlying chromosomal instability that leads to low tolerance to chemotherapy. To effectively manage cancer and immune risks, there is a need for improved HSCT protocols, novel therapies, and long-term monitoring. This report describes a 16-year-old boy with A-T and T-ALL who achieved long-term leukemia-free survival after HSCT using a tailored, drug-monitored conditioning regimen. His results were analyzed in the context of a systematic review of the literature on HSCT outcomes in A-T patients. Methods: A thorough literature review was conducted using a comprehensive search of the PubMed, Scopus, and Google Scholar databases. The search was limited to studies published between September 1, 2000, and September 1, 2025. Eligible studies were required to involve human participants and to include at least one patient with a confirmed diagnosis of A-T, with transplantation interventions. Results: The analysis included 16 A-T patients, including our patient, who underwent HSCT. The median age at transplantation was 48 months (interquartile range [IQR]: 22–142 months). Myeloablative conditioning (MAC) was administered to two patients, both of whom died. Reduced-intensity conditioning (RIC) was utilized for nine patients, with three deaths (33.3%). Reduced-toxicity conditioning (RTC) was administered in two patients, with one patient experiencing a fatal outcome. In total, eight patients (50%) experienced significant drug-related toxicities, eight (50%) had GvHD and only eight patients (50%) survived. Our patient underwent HSCT of a matched sibling donor after administration of adjusted treosulfan doses (cumulative AUC of 4671 mg/Lxh), and achieved leukemia-free survival with complete hematological and normalized thymic function without graft-versus-host disease (GvHD). Conclusion: Despite the historically poor survival outcomes observed in transplanted A-T patients, new HSCT strategies, such as treosulfan therapeutic drug monitoring and personalized drug profiles to select potent but less toxic agents, warrant reevaluation to achieve durable remission in leukemia and lymphoma. These findings underscore the necessity to persist in the development of innovative HSCT approaches with the objective of expanding therapeutic options for both malignancies and combined immunodeficiency.
- Open Access
- 3 October 2025
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 60 (6) , 572-576
Evaluating the Use of Nasal Epinephrine in Anaphylaxis: Current Status
The use of epinephrine auto-injectors is life-saving in serious allergic reactions such as out-ofhospital anaphylaxis. However, several factors limit their use, including patients not obtaining their prescriptions, the difficulty of carrying auto-injectors, and fear of injection. Administering epinephrine as early as possible to a patient experiencing anaphylaxis significantly reduces mortality and morbidity. Many experts are therefore interested in developing life-saving medical treatments in forms that are easier to access and apply. Nasal epinephrine consists of 3 components: epinephrine, a unit-dose spray, and İntravair. This spray was developed in collaboration with both the Food and Drug Administration and the European Medicines Agency. In addition to its ease of use, nasal epinephrine has shown favorable pharmacokinetic and pharmacodynamic (PD) responses for various symptoms, including allergic and infectious rhinitis. Notably, it has been found that nasal epinephrine provides a better PD response than injections; the increase in heart rate and blood pressure within 1 minute of administration confirms receptor activation in this drug’s mechanism of action. These findings indicate that nasal epinephrine could be a choice for the treatment of serious allergic reactions, including anaphylaxis, and could be safe and effective. Cite this article as: Bozkurt HB, Pen.e İ. Evaluating the use of nasal epinephrine in anaphylaxis: Current status. Turk Arch Pediatr. 2025;60(6):572-576.
- 3 October 2025
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 60 (6) , 572-576
Open AccessEvaluating the Use of Nasal Epinephrine in Anaphylaxis: Current Status
The use of epinephrine auto-injectors is life-saving in serious allergic reactions such as out-ofhospital anaphylaxis. However, several factors limit their use, including patients not obtaining their prescriptions, the difficulty of carrying auto-injectors, and fear of injection. Administering epinephrine as early as possible to a patient experiencing anaphylaxis significantly reduces mortality and morbidity. Many experts are therefore interested in developing life-saving medical treatments in forms that are easier to access and apply. Nasal epinephrine consists of 3 components: epinephrine, a unit-dose spray, and İntravair. This spray was developed in collaboration with both the Food and Drug Administration and the European Medicines Agency. In addition to its ease of use, nasal epinephrine has shown favorable pharmacokinetic and pharmacodynamic (PD) responses for various symptoms, including allergic and infectious rhinitis. Notably, it has been found that nasal epinephrine provides a better PD response than injections; the increase in heart rate and blood pressure within 1 minute of administration confirms receptor activation in this drug’s mechanism of action. These findings indicate that nasal epinephrine could be a choice for the treatment of serious allergic reactions, including anaphylaxis, and could be safe and effective. Cite this article as: Bozkurt HB, Pen.e İ. Evaluating the use of nasal epinephrine in anaphylaxis: Current status. Turk Arch Pediatr. 2025;60(6):572-576.
- Open Access
- 30 April 2025
- Published by Duzce Medical Journal in Düzce Tıp Fakültesi Dergisi
- Vol. 27 (1) , 75-80
Evaluation of Osteoarticular Involvement Associated with Brucellosis in Children
Aim: Brucellosis is a significant public health problem with high morbidity. Its most frequent complication is osteoarticular involvement. The study aimed to evaluate the relationship of osteoarticular involvement with clinical features and prognosis in children with brucellosis. Material and Methods: This retrospective study included pediatric patients between the ages of 1 and 18 years who were hospitalized and diagnosed with brucellosis between 2015 and 2020, and were regularly followed up. and all their findings and osteoarticular involvement data within the last two years were recorded. Clinical features, laboratory findings, osteoarticular involvement, and relapse rates of the patients were evaluated. Results: A total of 80 patients were included study. During the follow-up period, relapse developed in 14 (17.5%) patients. The most commonly affected joints were right (40%, n=32) and left (26.3%, n=21) hips, then right (27.5%, n=22) and left (23.8%, n=19) knees. Shoulder joint involvement rates and C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), alanine transaminase (ALT), and aspartate aminotransferase (AST) levels were statistically significantly higher in the relapse group (p=0.016, p=0.003, p=0.001, p
- 30 April 2025
- Published by Duzce Medical Journal in Düzce Tıp Fakültesi Dergisi
- Vol. 27 (1) , 75-80
Open AccessEvaluation of Osteoarticular Involvement Associated with Brucellosis in Children
Aim: Brucellosis is a significant public health problem with high morbidity. Its most frequent complication is osteoarticular involvement. The study aimed to evaluate the relationship of osteoarticular involvement with clinical features and prognosis in children with brucellosis. Material and Methods: This retrospective study included pediatric patients between the ages of 1 and 18 years who were hospitalized and diagnosed with brucellosis between 2015 and 2020, and were regularly followed up. and all their findings and osteoarticular involvement data within the last two years were recorded. Clinical features, laboratory findings, osteoarticular involvement, and relapse rates of the patients were evaluated. Results: A total of 80 patients were included study. During the follow-up period, relapse developed in 14 (17.5%) patients. The most commonly affected joints were right (40%, n=32) and left (26.3%, n=21) hips, then right (27.5%, n=22) and left (23.8%, n=19) knees. Shoulder joint involvement rates and C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), alanine transaminase (ALT), and aspartate aminotransferase (AST) levels were statistically significantly higher in the relapse group (p=0.016, p=0.003, p=0.001, p
- Open Access
- 28 April 2025
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 184 (5) , 1
Correction to: Evaluation of drug-related anaphylaxis in children: multi-center study
- 28 April 2025
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 184 (5) , 1
Open AccessCorrection to: Evaluation of drug-related anaphylaxis in children: multi-center study
- 7 March 2025
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 184 (3) , 1-11
Evaluation of drug-related anaphylaxis in children: multi-center study
The aim of the study is to elucidate demographic characteristics, risk factors, clinical presentations, causative agents, and management approaches pertaining to drug-related anaphylaxis in the paediatric population. This study is a multicenter retrospective study that included paediatric patients aged between 1 month and 18 years, who were admitted to the Pediatric Allergy and Immunology outpatient clinics of 11 participating centres with a presumptive diagnosis of drug-induced anaphylaxis, that fulfilled the standardised criteria for anaphylaxis, between January 2017 and December 2022. A total of 293 anaphylactic episodes presented among 265 patients, of which 48.1% (n 141) were female, were included. The median age of patients during the index episode was 107 months (IQR 56.5–161.5). Anaphylaxis occurred most frequently within hospital settings (62.1%, n 182) compared to home environments (34.1%, n 100). The administration were peroral in 40.3% (n 118), parenteral in 59.7% (n 175) of the cases. While antibiotics (56.7%), non-steroidal anti-inflammatory drugs (25.7%), and chemotherapeutics (3.4%) were the most commonly suspected drug groups, the cephalosporin group, and especially ceftriaxone (27.5% [n 80]) were the leading culprits among antibiotics. The anaphylaxis severity was severe in 39.6% (n 116), and moderate in 54.9% (n 161) of episodes. A biphasic reaction occurred in five patients. Only 72% (n 213) of patients were given adrenaline treatment. There were no fatalities. Diagnostic tests (n 64), including skin prick, intradermal, and drug provocation tests, which were performed between 1 and 120 months after the index reaction, yielded positive results in 23.4% (n 15), 17.2% (n 11), and 20.3% (n 13) of cases respectively, giving a total confirmation of 39 patients. Four patients underwent suspected drug desensitisation protocols. There were no fatalities. Conclusions: Antibiotics, particularly ceftriaxone, were the most commonly implicated agents in paediatric drug-induced anaphylaxis. Non-steroidal anti-inflammatory drugs, particularly ibuprofen, constituted the second most frequently implicated drug group. Paediatric patients experiencing drug-related anaphylaxis warrant algorithmic evaluation to ensure accurate diagnosis, prevent recurrence, and identify safe alternative treatments. What is Known: • Antibiotics, particularly ceftriaxone were the most frequently implicated culprit drugs, followed by NSAIDs, with ibuprofen being the most common within this group. What is New: • To the best of our knowledge, this is the largest multicenter paediatric drug-related anaphylaxis study, involving a large number of patients who evaluated by paediatric allergist. • We propose paediatric patients who experience drug induced anaphylaxis should undergo evaluation at specialized centres, to ensure accurate diagnosis, to prevent recurrence and identify safe alternative treatments.
- 7 March 2025
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 184 (3) , 1-11
Evaluation of drug-related anaphylaxis in children: multi-center study
The aim of the study is to elucidate demographic characteristics, risk factors, clinical presentations, causative agents, and management approaches pertaining to drug-related anaphylaxis in the paediatric population. This study is a multicenter retrospective study that included paediatric patients aged between 1 month and 18 years, who were admitted to the Pediatric Allergy and Immunology outpatient clinics of 11 participating centres with a presumptive diagnosis of drug-induced anaphylaxis, that fulfilled the standardised criteria for anaphylaxis, between January 2017 and December 2022. A total of 293 anaphylactic episodes presented among 265 patients, of which 48.1% (n 141) were female, were included. The median age of patients during the index episode was 107 months (IQR 56.5–161.5). Anaphylaxis occurred most frequently within hospital settings (62.1%, n 182) compared to home environments (34.1%, n 100). The administration were peroral in 40.3% (n 118), parenteral in 59.7% (n 175) of the cases. While antibiotics (56.7%), non-steroidal anti-inflammatory drugs (25.7%), and chemotherapeutics (3.4%) were the most commonly suspected drug groups, the cephalosporin group, and especially ceftriaxone (27.5% [n 80]) were the leading culprits among antibiotics. The anaphylaxis severity was severe in 39.6% (n 116), and moderate in 54.9% (n 161) of episodes. A biphasic reaction occurred in five patients. Only 72% (n 213) of patients were given adrenaline treatment. There were no fatalities. Diagnostic tests (n 64), including skin prick, intradermal, and drug provocation tests, which were performed between 1 and 120 months after the index reaction, yielded positive results in 23.4% (n 15), 17.2% (n 11), and 20.3% (n 13) of cases respectively, giving a total confirmation of 39 patients. Four patients underwent suspected drug desensitisation protocols. There were no fatalities. Conclusions: Antibiotics, particularly ceftriaxone, were the most commonly implicated agents in paediatric drug-induced anaphylaxis. Non-steroidal anti-inflammatory drugs, particularly ibuprofen, constituted the second most frequently implicated drug group. Paediatric patients experiencing drug-related anaphylaxis warrant algorithmic evaluation to ensure accurate diagnosis, prevent recurrence, and identify safe alternative treatments. What is Known: • Antibiotics, particularly ceftriaxone were the most frequently implicated culprit drugs, followed by NSAIDs, with ibuprofen being the most common within this group. What is New: • To the best of our knowledge, this is the largest multicenter paediatric drug-related anaphylaxis study, involving a large number of patients who evaluated by paediatric allergist. • We propose paediatric patients who experience drug induced anaphylaxis should undergo evaluation at specialized centres, to ensure accurate diagnosis, to prevent recurrence and identify safe alternative treatments.
- Open Access
- 22 January 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (3) , 712
Increasing Importance of Genotype–Phenotype Correlations Associated with Common and Rare MEFV Gene Mutations in FMF Patients in the Last Thirty Years
Background/Objectives: Studies have shown that some mutations, especially M694V, are correlated with renal RI and/or AA. There are limited data about rare mutations on severity of the disease and RI. Today, evaluating genotype–phenotype correlations in rare mutations is important to better understand FMF. We aimed to evaluate clinical, demographic and genetic changes and genotype–phenotype correlations in pediatric patients with FMF over thirty years as well as the importance of the rare mutations. Methods: A total of 2765 pediatric patients with FMF were included in this study. Genetic results were firstly divided into ten groups including rare mutations. Rare mutations were seen in 2% of all patients and divided into eight groups. Results: There was a significant increase in compound heterozygous mutations, E148Q het/hom, R202Q het/hom, complex mutations and rare mutations in the last decade. RI wo AA was 5.8% and AA was 1% in the patients with rare mutations. While M694V and compound het with M694V were positively correlated with severe PRAS, E148Q and V726A were negatively correlated with severe PRAS (p < 0.05, R = 0.137, R = −0.077, R= −0.05, respectively). Although K695R mutation was negatively correlated with severe PRAS (p < 0.05, R = −0.04), the rate of RI was 20%. Although the rare mutation R761H was negatively correlated with severe PRAS (p < 0.05, R = −0.051), the colchicine resistance rate was 8.3%. Conclusions: It may be misleading for clinicians that mutations which have increased in frequency over the years are clinically mild. RI and AA rates in rare mutations are not less than the related rates in common mutations.
- 22 January 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (3) , 712
Open AccessIncreasing Importance of Genotype–Phenotype Correlations Associated with Common and Rare MEFV Gene Mutations in FMF Patients in the Last Thirty Years
Background/Objectives: Studies have shown that some mutations, especially M694V, are correlated with renal RI and/or AA. There are limited data about rare mutations on severity of the disease and RI. Today, evaluating genotype–phenotype correlations in rare mutations is important to better understand FMF. We aimed to evaluate clinical, demographic and genetic changes and genotype–phenotype correlations in pediatric patients with FMF over thirty years as well as the importance of the rare mutations. Methods: A total of 2765 pediatric patients with FMF were included in this study. Genetic results were firstly divided into ten groups including rare mutations. Rare mutations were seen in 2% of all patients and divided into eight groups. Results: There was a significant increase in compound heterozygous mutations, E148Q het/hom, R202Q het/hom, complex mutations and rare mutations in the last decade. RI wo AA was 5.8% and AA was 1% in the patients with rare mutations. While M694V and compound het with M694V were positively correlated with severe PRAS, E148Q and V726A were negatively correlated with severe PRAS (p < 0.05, R = 0.137, R = −0.077, R= −0.05, respectively). Although K695R mutation was negatively correlated with severe PRAS (p < 0.05, R = −0.04), the rate of RI was 20%. Although the rare mutation R761H was negatively correlated with severe PRAS (p < 0.05, R = −0.051), the colchicine resistance rate was 8.3%. Conclusions: It may be misleading for clinicians that mutations which have increased in frequency over the years are clinically mild. RI and AA rates in rare mutations are not less than the related rates in common mutations.
- 31 December 2024
- Published by Journal of Biotechnology and Strategic Health Research in JOURNAL OF BIOTECHNOLOGY AND STRATEGIC HEALTH RESEARCH
- Vol. 8 (3) , 189-194
Allergic Reactions to Vaccines: Diagnosis and Management
Childhood vaccinations are the most cost-effective method to combat preventable diseases. Allergic reactions to vaccines are generally rare. However, all vaccines can potentially cause allergic reactions. These allergic reactions can develop against any of the components of the vaccine (adjuvant, microbial agent, stabilizer, residue antibiotic, cell culture, etc.). It is very important to correctly diagnose allergic reactions to vaccines because only 15% of suspected allergic reactions to vaccines are real allergic reactions and the continuation of immunization procedures is essential for public health. Allergic reactions to vaccines should be evaluated by an allergist-immunologist expert and a risk analysis should be performed. Vaccination of these children in a reliable way and guaranteed immunization procedure will also contribute to the protection of both children and public health. This study compiles the diagnosis of immediate and delayed reactions to vaccines or vaccine components and their management with current guidelines.
- 31 December 2024
- Published by Journal of Biotechnology and Strategic Health Research in JOURNAL OF BIOTECHNOLOGY AND STRATEGIC HEALTH RESEARCH
- Vol. 8 (3) , 189-194
Allergic Reactions to Vaccines: Diagnosis and Management
Childhood vaccinations are the most cost-effective method to combat preventable diseases. Allergic reactions to vaccines are generally rare. However, all vaccines can potentially cause allergic reactions. These allergic reactions can develop against any of the components of the vaccine (adjuvant, microbial agent, stabilizer, residue antibiotic, cell culture, etc.). It is very important to correctly diagnose allergic reactions to vaccines because only 15% of suspected allergic reactions to vaccines are real allergic reactions and the continuation of immunization procedures is essential for public health. Allergic reactions to vaccines should be evaluated by an allergist-immunologist expert and a risk analysis should be performed. Vaccination of these children in a reliable way and guaranteed immunization procedure will also contribute to the protection of both children and public health. This study compiles the diagnosis of immediate and delayed reactions to vaccines or vaccine components and their management with current guidelines.
- Open Access
- 1 January 2024
- Published by Kare Publishing in Ümraniye Pediatri Dergisi - Journal of Umraniye Pediatrics
- Vol. 4 (2) , 92-94
Bartter syndrome: A case report requiring emergency intervention
Bartter sendromu, hipokalemi, hipokloremik metabolik alkaloz ve hiperaldosteronizm ile hiperreninemiye rağmen normal kan basıncı ile karakterize otozomal resesif nadir bir genetik hastalıktır. Bartter sendromunun tedavisinde, dehidratasyonun giderilmesi, elektrolit dengesizliğinin düzeltilmesi, genel destek ve replasman tedavileri ile varsa eşlik eden enfeksiyonun tedavisi önceliklidir. Bu yazıda, 3 yaş 6 aylık Bartter sendromu tanısı ile takip edilen hasta, ayırıcı tanıda akılda tutulması ve farkındalığın artırılması amacıyla sunulmuştur. Bartter syndrome is a rare autosomal recessive genetic disease characterized by hypokalemia, hypochloremic metabolic alkalosis, and normal blood pressure despite hyperaldosteronism and hyperreninemia. In the treatment of Bartter syndrome, the priority is to eliminate dehydration, correct electrolyte imbalance, provide general support and replacement therapies, and treat any accompanying infection. In this article, a patient diagnosed with Bartter syndrome, aged 3 years and 6 months, was presented to highlight this condition in differential diagnosis and increase awareness.
- 1 January 2024
- Published by Kare Publishing in Ümraniye Pediatri Dergisi - Journal of Umraniye Pediatrics
- Vol. 4 (2) , 92-94
Open AccessBartter syndrome: A case report requiring emergency intervention
Bartter sendromu, hipokalemi, hipokloremik metabolik alkaloz ve hiperaldosteronizm ile hiperreninemiye rağmen normal kan basıncı ile karakterize otozomal resesif nadir bir genetik hastalıktır. Bartter sendromunun tedavisinde, dehidratasyonun giderilmesi, elektrolit dengesizliğinin düzeltilmesi, genel destek ve replasman tedavileri ile varsa eşlik eden enfeksiyonun tedavisi önceliklidir. Bu yazıda, 3 yaş 6 aylık Bartter sendromu tanısı ile takip edilen hasta, ayırıcı tanıda akılda tutulması ve farkındalığın artırılması amacıyla sunulmuştur. Bartter syndrome is a rare autosomal recessive genetic disease characterized by hypokalemia, hypochloremic metabolic alkalosis, and normal blood pressure despite hyperaldosteronism and hyperreninemia. In the treatment of Bartter syndrome, the priority is to eliminate dehydration, correct electrolyte imbalance, provide general support and replacement therapies, and treat any accompanying infection. In this article, a patient diagnosed with Bartter syndrome, aged 3 years and 6 months, was presented to highlight this condition in differential diagnosis and increase awareness.
- 23 June 2023
- Published by Bilimsel Tip Publishing House in Journal of Pediatric Infection
- Vol. 17 (2) , 88-95
Use of Gentamicin for Childhood Brucellosis: Effect on Calcium Homeostasis and Relapse
- 23 June 2023
- Published by Bilimsel Tip Publishing House in Journal of Pediatric Infection
- Vol. 17 (2) , 88-95
Use of Gentamicin for Childhood Brucellosis: Effect on Calcium Homeostasis and Relapse